GZR4
Sponsors
Gan and Lee Pharmaceuticals, USA, Gan & Lee Pharmaceuticals.
Conditions
Diabetes
Phase 1
Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment
CompletedNCT06547502
Start: 2024-07-03End: 2024-09-05Updated: 2024-12-09
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single-dose GZR4
CompletedNCT06548815
Start: 2022-08-29End: 2023-03-24Updated: 2024-08-12
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes
CompletedNCT06553248
Start: 2023-03-22End: 2023-11-01Updated: 2024-08-14
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
Active, not recruitingNCT07193147
Start: 2025-10-20End: 2026-11-04Target: 36Updated: 2025-11-28
Phase 3
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin
Active, not recruitingNCT06767761
Start: 2025-02-18End: 2026-04-09Target: 580Updated: 2025-11-25
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Active, not recruitingNCT06767748
Start: 2025-02-15End: 2026-02-28Target: 620Updated: 2025-11-21
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
Active, not recruitingNCT06767735
Start: 2025-02-17End: 2026-08-17Target: 580Updated: 2025-11-28
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
RecruitingNCT07165223
Start: 2025-10-17End: 2026-11-10Target: 300Updated: 2025-11-25